secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001104659-26-020494
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics posts Q4 net income; aleniglipron up to 15.3% weight loss in Phase 2
--------------------------------------------------------------------------------

- Q4 2025 net income $33.0M vs. net loss of $36.5M in Q4 2024; full-year net loss $141.2M.
- Cash, equivalents and investments $1.4B as of Dec 31, 2025, funding through end of 2028.
- Aleniglipron Phase 2 ACCESS II: placebo-adjusted weight loss up to 15.3% with 240 mg at 36 weeks.
- Phase 3 for aleniglipron expected in H2 2026; topline 44-week data from ACCESS II due Q1 2026.
- Oral amylin agonists: ACCG-2671 in Phase 1; ACCG-3535 to enter Phase 1 in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/0001104659-26-020494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/tm267321d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-020494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer